Skip to content
Market

Peptide Manufacturing Ramps Up: Vector Science Begins Production

Vector Science's LyoGenesis facility began producing pharma-grade peptides Aug 24 — 55,000 vials monthly now, up to 800,000 planned as compounding demand grows.

By PeptidesBeat Staff

Last reviewed

Vector Science & Therapeutics (TSXV: PAIN) said on August 24 that the first of four manufacturing suites at its LyoGenesis facility in Mequon, Wisconsin is now producing pharma-grade peptides, putting the company on track to begin fulfilling existing customer orders for nine peptides this month (source). The start marks an early concrete milestone in the U.S. peptide manufacturing buildout that has followed the FDA’s April 15 reclassification of 12 peptides — and it comes about a month after a federal advisory committee recommended six peptides for the 503A Bulks List.

What the production milestone includes

The first LyoGenesis suite is capable of producing approximately 55,000 vials per month, and that capacity is already presold, according to the company. The three remaining suites are expected to come online in the latter half of September 2026, each with a substantially larger production profile, giving the company combined capacity to produce up to 800,000 vials of peptides per month.

Vector says it expects to scale to approximately 200,000 vials per month within the next three months as additional capacity comes online, and that one major customer has signaled it expects to commit to purchasing 200,000 vials per month within three months. After accounting for LyoGenesis production costs, the company says it expects to retain a margin of roughly 80% on each sale, reflecting the premium that pharma-grade peptides command over research-grade material that lacks comparable manufacturing, quality, and regulatory rigor.

The announcement follows an extensive qualification process required to bring each suite into cGMP, FDA, and ISO compliance — the same quality distinction that has been central to the May agreement that originally tied Vector to the LyoGenesis facility.

The nine peptides in production

Outside the GLP-1 class, Vector says it will focus production on Sermorelin, BPC-157, NAD, TB-500, PT-141, KPV, Semax, Epitalon, and MOTS-c to meet growing U.S. demand. Six of the nine — BPC-157, TB-500, KPV, Semax, Epitalon, and MOTS-c — are exactly the peptides the FDA’s Pharmacy Compounding Advisory Committee discussed and voted to recommend for the 503A Bulks List at its July 23-24 meeting, which covered seven substances total. The FDA’s final 503A Bulks List decision remains pending; the committee’s vote was advisory.

The alignment suggests at least one manufacturer is committing capacity to the same compounds the advisory process is moving toward formal listing. BPC-157, TB-500, KPV, Semax, Epitalon, and MOTS-c all have dedicated PeptidesBeat compound guides covering their research and regulatory status.

Why pharma-grade capacity matters

The company explicitly positions its output against the research-chemical market, stating that its material carries manufacturing, quality, and regulatory rigor that lower-cost research-grade product lacks. All peptides produced at LyoGenesis undergo validated testing by Verlytix, the facility’s related-company quality and analytical testing affiliate, confirming sterility, purity, potency, endotoxin levels, and water content.

Endotoxin screening is a concrete differentiator in the current market. Two Texas compounding pharmacies recalled injectable glutathione in August 2026 over elevated endotoxin levels, part of an active peptide recall pattern that safety organizations have flagged as a persistent wellness-peptide risk. A growing share of U.S. peptide supply is moving toward tested, cGMP-manufactured product as state boards and federal enforcement tighten scrutiny of the unregulated segment.

Leadership on the milestone

“We projected we would begin producing revenue from the Mequon facility, and we met our timeline because of the effort our entire team put in,” said Tommy Thompson, chairman of Vector Science & Therapeutics and former Wisconsin governor and U.S. Secretary of Health and Human Services. “This is a significant milestone that allows us to begin to meet the commitments we’ve made to our customers.”

“Every suite goes through the same rigorous qualification process before it can produce a single vial,” said Bill Jackson, chief executive officer. “That discipline is what allows us to stand behind the quality of what leaves this facility, and it’s what our partners and their patients are counting on.”

What to watch

Three developments will determine whether this capacity finds a market. First, the FDA’s final 503A Bulks List decision, which will settle the compounding status of the six recommended peptides. Second, whether the September suite launches hit their stated timeline and the 800,000-vials-per-month target. Third, whether pharmacy demand absorbs presold capacity and the anticipated 200,000-vials-per-month commitment materializes. Vector’s peptides are development-stage and investigational; the company states they have not been approved for any indication.

Sources

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.

Educational content, not medical advice. © 2026 PeptidesBeat.